An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study comparing pharmacokinetic and pharmacodynamic effects of Neutrogen (Filgrastim) of Virchow Biotech, India with that of Neupogen (filgrastim) of Roche following 5 mcg/kg subcutaneous injection in healthy, adult human subjects

Trial Profile

An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study comparing pharmacokinetic and pharmacodynamic effects of Neutrogen (Filgrastim) of Virchow Biotech, India with that of Neupogen (filgrastim) of Roche following 5 mcg/kg subcutaneous injection in healthy, adult human subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Virchow Group
  • Most Recent Events

    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top